Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma

Jason Wachsmann, Fangyu Peng

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Significant efforts have been devoted to identify new biomarkers for molecular imaging and targeted therapy of HCC. Copper is a nutritional metal required for the function of numerous enzymatic molecules in the metabolic pathways of human cells. Emerging evidence suggests that copper plays a role in cell proliferation and angiogenesis. Increased accumulation of copper ions was detected in tissue samples of HCC and many other cancers in humans. Altered copper metabolism is a new biomarker for molecular cancer imaging with position emission tomography (PET) using radioactive copper as a tracer. It has been reported that extrahepatic mouse hepatoma or HCC xenografts can be localized with PET using copper-64 chloride as a tracer, suggesting that copper metabolism is a new biomarker for the detection of HCC metastasis in areas of low physiological copper uptake. In addition to copper modulation therapy with copper chelators, short-interference RNA specific for human copper transporter 1 (hCtr1) may be used to suppress growth of HCC by blocking increased copper uptake mediated by hCtr1. Furthermore, altered copper metabolism is a promising target for radionuclide therapy of HCC using therapeutic copper radionuclides. Copper metabolism has potential as a new theranostic biomarker for molecular imaging as well as targeted therapy of HCC.

Original languageEnglish (US)
Pages (from-to)221-231
Number of pages11
JournalWorld Journal of Gastroenterology
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 7 2016

    Fingerprint

Keywords

  • Copper metabolism
  • Gene therapy
  • Hepatocellular carcinoma
  • Positron emission tomography
  • Radionuclide therapy
  • RNA interference

ASJC Scopus subject areas

  • Gastroenterology

Cite this